Clin2
NCT07467993Possibly a fitRecruiting

Testing GXV813 for hospitalized adults with schizophrenia

Schizophrenia

Part of Mental health clinical trials.

This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
142 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have a diagnosis of schizophrenia and are now experiencing a sudden worsening of symptoms that started within the past 2 months.
  • You are currently in the hospital due to this worsening, or have been hospitalized for less than 2 weeks.
  • You are not currently taking a long-acting injectable antipsychotic, or if you are, it has been at least 12 weeks since your last dose (24 weeks for one specific type).
  • You have not been considered treatment-resistant (for example, you have never needed clozapine or have not failed two different antipsychotic trials).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06894212Recruiting· Phase 3
Testing a new med for schizophrenia flare-ups

This trial tests a new medication called SEP-363856 for people with schizophrenia who are currently having a severe flare-up of symptoms. It aims to see if the drug is safe and effective compared to a placebo.

Bentonville, Arkansas
NCT07686263Not yet recruiting· Phase 3
Testing a new drug to prevent schizophrenia relapse

This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.

Bentonville, Arkansas
NCT07363577Recruiting· Phase 3
Testing LB-102 for adults with acute schizophrenia

This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.

Bentonville, Arkansas
NCT07703956Not yet recruiting· Phase 2
Testing VV119 for acute schizophrenia in adults

This trial tests a new medication called VV119 for adults currently experiencing a sudden worsening of schizophrenia symptoms. The goal is to see if it is safe and if it helps reduce symptoms like delusions, disorganized thinking, and hallucinations.

Beijing, Beijing Municipality
NCT07105098Recruiting· Phase 3
Study of a new drug for schizophrenia in hospitalized adults

This study tests an experimental drug (NBI-1117568) for people with schizophrenia who are currently in the hospital due to worsening symptoms. Participants stop their current antipsychotic and take the study drug to see if it can help control symptoms.

Culver City, California
NCT07288333Recruiting· Phase 2
New medication for schizophrenia in hospitalized adults

This study tests an experimental medication (NBI-1117570) for adults with schizophrenia who are currently in the hospital because of a sudden worsening of symptoms. The goal is to see if this new treatment can help control symptoms better.

Kazanlak

Hear when a new Schizophrenia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.